In the Original Investigation “Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis,”1 there was an error in the Discussion. The mortality rate in the COViMS Registry (3.3%) is higher, rather than lower, than the US mortality rate (1.8%). This article was corrected online.